Image

ICMR Licenses Three Medical Technologies

ICMR Licenses Three Medical Technologies

Overview :

ICMR transferred three medical technologies to Emcure and Biological E on 21 July 2026. The technologies include SHetA2, a novel anti-HPV therapeutic, and two vaccine technologies for typhoid and other bacterial infections. The transfers happened under the Medical Innovations Patent Mitra initiative for commercialisation.

What Is Medical Innovations Patent Mitra?

Medical Innovations Patent Mitra is an ICMR initiative. It focuses on technology transfer and commercialisation. The programme supports publicly funded biomedical research.

It connects research institutions with industry partners. The goal is product development, licensing, and scale-up. This ensures that research reaches the public. It moves from lab to market.

The Three Technologies Transferred

ICMR licensed three key technologies. Each has significant public health potential.

1. SHetA2 (To Emcure Pharmaceuticals)

SHetA2 is a novel anti-HPV therapeutic candidate. It targets Cervical Intraepithelial Neoplasia (CIN). This is a precancerous condition of the cervix.

Human papillomavirus (HPV) is a major cause of cervical cancer. CIN is a precursor lesion. SHetA2 aims to treat this condition early. This could prevent cervical cancer.

Scientists developed SHetA2 through collaboration. Dr. Showket Hussain of ICMR-NICPR worked with Dr. Doris M. Benbrook of the University of Oklahoma, USA. The technology now goes to Emcure for further development.

2. Typhoid Vaccine Technology (To Biological E)

Biological E received a licence for a fusion protein-based typhoid vaccine. It targets Salmonella typhi. This bacterium causes typhoid fever. Typhoid remains a major public health problem in India.

3. Broad-Spectrum Vaccine Technology (To Biological E)

Biological E also received a licence for a recombinant vaccine. This one offers broader protection. It targets Salmonella typhi, Salmonella paratyphi, and Shigella infections.

Paratyphoid fever is associated with Salmonella paratyphi. Shigella species cause bacillary dysentery. A single vaccine targeting all three would be a breakthrough.

Development and Collaboration

The vaccine technologies were developed at ICMR-NIRBI in Kolkata. NIRBI stands for National Institute for Research in Bacterial Infections. The institute focuses on bacterial diseases.

These technologies are next-generation vaccines. They use advanced approaches. The fusion protein-based vaccine is a modern design. The recombinant vaccine offers broader protection.

Earlier Technology Transfer Event

This is not a one-off event. On 25 May 2026, ICMR conducted a larger event. They transferred 41 public health technologies.

These included glycoconjugate and recombinant vaccines for typhoid and paratyphoid. They also included diagnostic technologies for Japanese Encephalitis, Tuberculosis, and Mpox. These transfers are part of India's public health research ecosystem.

Analogy: A Recipe Book

Imagine a research institute as a chef. The chef develops new recipes. These recipes are innovative and delicious. But only a few people can taste them. The chef needs a restaurant to serve the public.

The Medical Innovations Patent Mitra is like a restaurant chain. It connects the chef with restaurant owners. The owners produce the recipes at scale. They serve them to the public.

ICMR is the chef. Emcure and Biological E are the restaurant owners. The technologies are the recipes. The public gets the benefit.

Why This Matters for Exams

This news is relevant for:

  • Health:  Public health, vaccine development, cervical cancer prevention.

  • Economy:  Technology transfer, commercialisation, industry-academia collaboration.

  • Science:  Biotechnology, vaccine research.

  • Current Affairs:  Important for UPSC and state exams.


Exam-Focused Points :

  1. Organiser:  ICMR (Indian Council of Medical Research).

  2. Date:  21 July 2026.

  3. Initiative:  Medical Innovations Patent Mitra.

  4. Companies:  Emcure Pharmaceuticals and Biological E Ltd.

  5. SHetA2:  Anti-HPV therapeutic for Cervical Intraepithelial Neoplasia.

  6. Vaccines:  Typhoid vaccine and broad-spectrum vaccine for typhoid, paratyphoid, and Shigella.

  7. Developers:  ICMR-NICPR and ICMR-NIRBI.


FAQs :

Q1: What is Medical Innovations Patent Mitra?
Ans: An ICMR initiative for technology transfer and commercialisation of biomedical research.

Q2: Which companies received licences from ICMR?
Ans: Emcure Pharmaceuticals Ltd. and Biological E Ltd.

Q3: What is SHetA2?
Ans: A novel anti-HPV therapeutic for Cervical Intraepithelial Neoplasia.

Q4: Where were the vaccine technologies developed?
Ans: At ICMR-National Institute for Research in Bacterial Infections (NIRBI), Kolkata.

Q5: What is the earlier technology transfer event related to this?
Ans: ICMR transferred 41 public health technologies on 25 May 2026.

Month: 

Category: 

1